Drugs / TENDU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04701021 | Feb 2021 → Aug 2023 | prostate cancer | Ultimovacs ASA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-12-18 | Zelluna Immunotherapy AS | Results Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint zelluna.com ↗
Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpoint |
| 2022-08-18 | Zelluna Immunotherapy AS | Results Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review zelluna.com ↗
The TENDU interim safety results from nine patients show no safety concerns |
| 2022-02-03 | Zelluna Immunotherapy AS | Results Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study zelluna.com ↗
The Drug Safety Monitoring Board (DSMB), a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns related to the first two dose cohorts. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-18 | Zelluna Immunotherapy AS | Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint zelluna.com ↗ |
| 2022-12-14 | Zelluna Immunotherapy AS | Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer zelluna.com ↗ |
| 2022-08-18 | Zelluna Immunotherapy AS | Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review zelluna.com ↗ |
| 2022-02-03 | Zelluna Immunotherapy AS | Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study zelluna.com ↗ |
| 2021-10-01 | Zelluna Immunotherapy AS | Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine zelluna.com ↗ |
| 2021-02-18 | Zelluna Immunotherapy AS | Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine zelluna.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TENDU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04701021 ↗ |
| Modality | Vaccine | “TENDU is a synthetic therapeutic peptide conjugate vaccine” NCT04701021 ↗ |
| Route | Subcutaneous | “The vaccine is administrated by subcutaneous injections” NCT04701021 ↗ |